08:00 , Nov 12, 2015 |  BC Innovations  |  Translation in Brief

First world problems

As the microbiome sheds its status as fringe science and moves to the mainstream, leading researchers are grappling with how to solve problems and create common standards that will set the field on the right...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Harvard Scientific Corp, Biosphere Technologies Inc deal

HVSF acquired exclusive rights to Prostaglandin E-1 Lyophilized Liposomes to treat psoriasis from its parent company, Biosphere Technologies. (HVSF to start clinical trials, B11). Harvard Scientific Corp . (HVSF), Reno, Nev.   Biosphere Technologies Inc...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Company News

BioSphere, Merit Medical Systems deal

Merit closed its acquisition of BioSphere for $96 million in cash (see BioCentury, May 24). BioSphere Medical Inc. , Rockland, Mass.   Merit Medical Systems Inc. (NASDAQ:MMSI), South Jordan, Utah   Business: Genitourinary, Cancer, Cardiovascular...
07:00 , May 24, 2010 |  BC Week In Review  |  Company News

BioSphere, Merit Medical Systems deal

Device company Merit will acquire BioSphere for $4.38 per share, or about $96 million in cash. The price is a 46% premium to BioSphere's close of $3 on May 13, before the deal was announced....
08:00 , Feb 9, 2009 |  BC Week In Review  |  Company News

Molecular Insight management update

Molecular Insight Pharmaceuticals Inc. (NASDAQ:MIPI), Cambridge, Mass.   Business: Cancer, Cardiovascular, Diagnostic   Transitioned: John Babich to CEO from interim chairman and CEO while remaining president and CSO; Anthony Martin, a director, becomes non-executive chairman...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Clinical News

HepaSphere Microspheres regulatory update

BSMD received CE Mark approval in the EU for use of its HepaSphere Microspheres to deliver doxorubicin in transarterial chemoembolization procedures to treat hepatocellular carcinoma. As a condition of the approval, the company has agreed...
08:00 , Nov 8, 2004 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion BioMarin (BMRN; SWX:BMRN) SG Cowen Phil Nadeau Other In line Nadeau raised his FY04 revenue estimate to $4.7M from $4.6M but lowered his FY05 revenue estimate...
08:00 , Nov 1, 2004 |  BC Week In Review  |  Company News

Ciphergen, Pall deal

PLL will acquire CIPH's BioSepra chromatography business for $32 million, net of cash and debt. CIPH retained certain rights to BioSepra's chromatography sorbent technology for research and diagnostic purposes. The companies also partnered to develop...
07:00 , Oct 28, 2004 |  BC Extra  |  Company News

Pall buying Ciphergen's chromatography business

PLL will acquire CIPH's BioSepra chromatography business for $32 million, net of cash and debt. CIPH retained certain rights to BioSepra's chromatography sorbent technology for diagnostic purposes. Invitrogen (IVGN) sold the BioSepra business to CIPH...
07:00 , Jul 5, 2004 |  BioCentury  |  Finance

Ebb & Flow

Three European companies picked their markets last week and two have hedged their bets by looking to NASDAQ as well as their home markets. Cell cycle company Cyclacel said on Friday that it plans to...